Alnylam Pharmaceuticals Inc (ALNY) Quote - XNAS | Morningstar

Skip to Content

Is it the right time to buy or sell?

Find out with Morningstar Premium

Is it the right time to buy or sell?

Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Narrow-Moat Alnylam Misses Q3 Revenue Estimates and Founding CEO Retires; Maintaining $158 FVE

Equity Analyst Rachel Elfman

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman | Nov 4, 2021

Investors reacted negatively as Alnylam’s third-quarter results missed FactSet consensus estimates. During the quarter, Alnylam lost $1.72 per share, lower than FactSet consensus of a $1.59 loss per share. Nevertheless, Alnylam’s loss narrowed from negative $2.18 in the prior-year period. While sales grew 49% year over year to nearly $188 million, this was also behind FactSet estimates ($217 million). Additionally, management announced that its founding CEO, Dr. John Maraganore, will retire at the end of this year and transition CEO leadership to Alnylam’s current president and COO, Dr. Yvonne Greenstreet.

Read Full Analysis

Company Profile

Business Description

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Contact

675 West Kendall Street, Henri A. Termeer Square
Cambridge, MA, 02142

T +1 617 551-8200

investors@alnylam.com

www.alnylam.com

Sector Healthcare

Industry Biotechnology

Most Recent Earnings Sep 30, 2021

Fiscal Year End Dec 31, 2021

Stock Type Speculative Growth

Employees 1,453

Related

10 Promising Stocks to Consider

These companies are growing their competitive advantages--and their stocks are undervalued.

Susan Dziubinski

Stock Strategist

Moderna's Innovation Still Building a Moat

The company's COVID-19 vaccine has shown the vast potential of its mRNA technology.

An Excellent Choice for Broad Exposure to Healthcare

Gold-rated Vanguard Health Care benefits from an experienced manager.

The Year in U.S. Equity Funds, 2019

A very good year for the market.

The Second Quarter in U.S. Stock Funds: Settling Down

After two volatile quarters, domestic stock funds took a breather.

A Superb Large Growth Fund For Your Watchlist

Managed by Morningstar's 2017 Domestic-Stock Fund Manager of the Year, Silver-rated Fidelity Growth Company has crushed its actively-managed competitors.

Katie Rushkewicz Reichart

Wymer: Stock Market Pullback Possible This Year

Stock market fundamentals are healthy, but recent strong returns are unlikely to continue, says Fidelity Growth Company manager Steve Wymer, 2017 Domestic-Stock Fund Manager of the Year.

Katie Rushkewicz Reichart

Stock Analyst Update

Boosting Fair Value on Alnylam After Drug Trial

Based on the stellar results and clean safety profile, we think patisiran will likely receive approval in the U.S. and Europe in 2018, which drives our fair value change and peak sales estimates near $1 billion.

Stock Analyst Update

Alnylam's Prospects Today

Though we've lowered our fair-value estimate of the drugmaker after it announced that it has stopped development of a key drug, we still believe in the potential of Alnylam’s remaining pipeline.

Dodge & Cox Balanced Fund Isn't for Everyone

This Gold-rated fund is not a safe choice, but it's a strong one for the right kind of investor.

Stock Strategist

Competition Rising for Baxalta

The newly independent firm still has a narrow moat, however.

Europe Tracks Asia Down

European Stocks Edge Up at Open

Will 'Knockout' Mice Make a Knockout Stock?

After a strong runup from our recommendation, is it time to take money off the table in Lexicon Pharmaceuticals?

Erik Kobayashi-Solomon

Stock Strategist

Betting on Biotech: The Mispriced and Fiscally Fit

These biotechs have the potential to provide a safe haven from market chaos.

Stock Strategist Industry Reports

Betting on Biotech: The Mispriced and Fiscally Fit

These biotechs have the potential to provide a safe haven from market chaos.

Quarter-End Insights

Our Outlook for the Health-Care Sector

Political winds could cast a cloud over health-care companies.

Transparency is our policy. Learn how it impacts everything we do.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.